SCHEMBL6314302

SCHEMBL6314302

CSc1nc(N)nc(CN2CCC(C)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
KMT2A Q03164 2/20 0.40
HSP90AB1 P08238 1/20 0.39
ACHE P22303 4/20 0.37
HRH3 Q9Y5N1 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
POLB P06746 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314269 0.82 L3MBTL1 (0.44) HSP90AA1HRH3SMN1; SMN2POLBALDH1A1
SCHEMBL6307171 0.82 GAA (0.50) HSP90AA1HSP90AB1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL6308323 0.74 ALDH1A1 (0.45) KMT2APOLBALDH1A1MAPK1GAA
SCHEMBL6307060 0.71 ALDH1A1 (0.64) KMT2ASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL6307905 0.71 CYBB (0.58) KMT2ASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL6310015 0.70 ALDH1A1 (0.50) KMT2ASMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL6310022 0.70 ALDH1A1 (0.50) KMT2ASMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL14375250 0.68 ACHE (0.38) KMT2AACHEHRH3POLBALDH1A1
SCHEMBL17828173 0.66 ACHE (0.45) KMT2AACHEHRH3ALDH1A1
SCHEMBL6309367 0.65 HSP90AB1 (0.39) HSP90AA1HSP90AB1HRH3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919339-B2 ABCA-1 elevating compounds CV THEAPEUTICS, INC. (US) 2005-07-19 US disclosed
EP-1341773-A2 SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-09-10 EP disclosed
US-20020128266-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2002-09-12 US disclosed
WO-2002046172-A2 SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128266-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 HSP90AA1 1676/4885KMT2A 3796/4885HSP90AB1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.